Dr. Jim Januzzi and Dr. C. Michael Gibson discuss the findings from the randomized controlled ATTRIBUTE-CM trial examining the relationship between these biomarkers and clinical outcomes in transthyretin amyloid cardiomyopathy.
Sponsored by an independent educational grant from BridgeBio Inc.